
    
      This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with
      moderate AD. Eligible subjects will be enrolled and randomized to treatment with BTX 1204 or
      Vehicle for 84 days. Approximately two hundred (200) subjects will be enrolled. Subjects will
      receive BID application of study drug for 84 days with a final application on the evening of
      Day 84 for a total of 168 doses.
    
  